

Table S1. Results distribution of molecular and serological analysis in humans, canines and felines population.

Species	Clinical Presentation (number)	Clinical samples (number)	IFAT ¹ Positive/total	qPCR ² Positive/total	Positive patients selection
Humans	VL ³ (135)	Serum (341)	100/341	n.a. ⁴	- 110 VL qPCR positive, IFAT positive;
		Bone marrow (341)	n.a.	135/341	- 25 VL qPCR positive, IFAT negative;
	CL ⁵ (332)	Tissue/skin biopsy (699)	n.a.	322/699	- 322 CL qPCR positive;
Canine	CanL ⁶ (23794)	Serum (74349)	23794/74349	n.a.	-22755 CanL qPCR positive, IFAT positive;
		Popliteal lymphnode (74349)	n.a.	23794/74349	- 1035 CanL IFAT positive, qPCR negative; - 4 CanL qPCR positive, IFAT negative;
Feline	FeL ⁷ (274)	Serum (4774)	109/4774	n.a.	-109 FeL qPCR positive, IFAT positive;
		Popliteal lymph node (4774)	n.a.	274/4774	- 165 FeL qPCR positive, IFAT negative;

¹IFAT, indirect immunofluorescent assay; ²qPCR, quantitative PCR; ³VL, visceral leishmaniasis; ⁴n.a., not applicable; ⁵CL, cutaneous leishmaniasis; ⁶CanL, canine leishmaniasis; ⁷FeL, feline leishmaniasis.